AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares rose 7.7% during mid-day trading on Thursday . The company traded as high as $24.55 and last traded at $24.02, with a volume of 1,179,051 shares traded. The stock had previously closed at $22.31.

AMAG has been the topic of a number of analyst reports. Deutsche Bank AG cut their price objective on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday, May 9th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 29th. Jefferies Group reaffirmed a “buy” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, June 2nd. Leerink Swann dropped their target price on shares of AMAG Pharmaceuticals from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 4th. Finally, Raymond James Financial Inc. downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 4th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $40.60.

The company’s 50 day moving average is $25.33 and its 200 day moving average is $23.71. The firm has a market capitalization of $845.09 million and a price-to-earnings ratio of 81.74.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.25. The business had revenue of $127.40 million for the quarter, compared to analyst estimates of $128.52 million. During the same period in the prior year, the company posted $1.12 EPS. The firm’s revenue for the quarter was up 46.7% compared to the same quarter last year. On average, equities analysts predict that AMAG Pharmaceuticals Inc. will post $5.33 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of AMAG. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares during the period. Rhumbline Advisers boosted its stake in shares of AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares during the period. Bank of Montreal Can boosted its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares during the period.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.